COVID-19 Update: Get the latest information and updates regarding VIPER response to COVID-19. More information viper.ac.in/coronavirus

Faculty

Professor & Head - Dr.V.V.S.Rajendra Prasad

Dr.V.V.S.Rajendra Prasad
HOD & Professor
Department of Pharmaceutical Analysis
This email address is being protected from spambots. You need JavaScript enabled to view it.
9703698214

Ph.D: RGUHS - Pharmaceutical Chemistry-2008

PG: RGUHS - M.Pharm-Pharmaceutical Chemistry-2005

UG: RGUHS - B.Pharmacy-2001

Total Teaching Experience: 16 years

R&D Experience: 03

College Employee ID : VIPER-003

JNTUH Registration ID : 1038-150408-121059

Employement Status: JNTUH Ratified 

Awards and Recognitions: 
Career Award for Young Teachers by AICTE.
Fast Track Young Scientist Award by DST.
SIPRA Innovation Award-2015.
Research grant received for the Project titled "Nitric oxide releasing Quinilones derivatives as inhibitors of doxorubicine resistance in cancer" sanctioned by AICTE, Government of India under RPS Scheme.Principal Investigator (PI): Dr.VVS Rajendra Prasad.

 

Fields of Specialization:
Pharmaceutical Chemistry, Pharmaceutical Analysis and Cancer Biology.

Research Papers Published:
1.    Siva Jyothi B, Mani Chandrika, Harathi P, G Deepak Reddy, V.V.S. Rajendra Prasad* “Novel 2,4-disubstituted Quinazolines as Cytotoxic Agents and JAK2 Inhibitors: Synthesis, In vitro Evaluation and Molecular Dynamics Studies ” Computational Biology and Chemistry, 79 (2019) 110–118. [Publisher: Elsevier, IF: 2.7].
2.    Deepak Reddy, Amareswararao M, Rajesh Babu Y, Godefridus J. Peters, B.S. Sastry, V.V.S. Rajendra Prasad* “Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies” Computational Biology and Chemistry, 74 (2018) 63–75. [Publisher: Elsevier, IF: 2.7].
3.    V.V.S.Rajendra Prasad*, G. Deepak Reddy, Ietje Kathmann, G.J. Peters “Design and synthesis of nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/dx cells” Bio-organic Chemistry, 64 (2016) 51-58 [Publisher: Elsevier, IF: 4.02].
4.    Y. Rajesh Babu , M. Bhagavanraju, G. Deepak Reddy, G.J.Peters, V.V.S. Rajendra Prasad* “Design and synthesis of Quinazolinone Tagged Acridones as Cytotoxic Agents and their EGFR Tyrosine Kinase Inhibition Studies” Arch. Pharm. Chem. Life Sci. 2014, 347, 1–11. [Publisher: Wiley Interscience, IF: 2.04].
5.    P. Chaitanya, G. Deepak Reddy, G. Varun, L.M. Srikanth, V.V.S. Rajendra Prasad* “Design and Synthesis of quinazolinone derivatives as anti-inflammatory agents: Pharmacophore modeling and 3D QSAR studies” Medicinal Chemistry, 2014, 10, 711-723 [Publisher: Bentham, IF: 2.60].
6.    G Deepak Reddy, K Pavan Kumar, R Divya, K Pavan Kumar Reddy, VVS Rajendra Prasad*. Quantum Polarized Molecular Docking, Pharmacophore Modeling and 3D-QSAR Studies of Pyrido-Indole Containing JAK2 Inhibitors. Journal of Receptors and Signal Transduction. 2014, 13, 23-34. [Publisher: Informa Healthcare. Impact Factor: 2.11].
7.    V.V.S.Rajendra Prasad*, G.Deepak Reddy, D.Appaji, G.J.Peters, Y.C Mayur. “Chemosensitizing acridones: In vitro calmodulin dependent cAMP Phosphodiesterase inhibition, docking, pharmacophore modeling and 3D QSAR studies” Journal of Molecular Graphics and Modeling, 40 (2013) 116–124. [Publisher: Elsevier, IF: 2.8].
8.    V.V.S.Rajendra Prasad, G.J.Peters, Clara Lemos, Ietje Kathmann, Y.C Mayur. “Cytotoxicity Studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies, European Journal of Pharmaceutical Sciences, 43 (2011) 217–224. [Publisher: Elsevier, IF: 3.82].
9.    M.Purohit, V.V.S. Rajendra Prasad, and Y.C. Mayur. Synthesis and Cytotoxicity of Bis-1,3,4-oxadiazoles and Bis-pyrazoles Derived from 1,4-Bis[5-thio-4-substituted-1,2,4- triazol-3-Yl]-butane and Their DNA Binding Studies. Arch. Pharm. Chem. Life Sci. 2011, 344, 1–7. [Publisher: Wiley Interscience, IF: 2.04].
10.    Y.C. Mayur, G.J. Peters, V.V.S.Rajendra Prasad “Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells” Current Cancer Drug Targets, 9 (2009) 298-306. [Publisher: Bentham, IF: 4.3].
11.    V.V.S.Rajendra Prasad, J. Venkat Rao, R.S.Giri , N.K.Sathish, S.M.Shanta Kumar Y.C.Mayur. “Chloro acridone derivatives as cytotoxic agents active on multidrug resistant cell lines and their duplex DNA complex studies by electrospray ionization mass spectrometry” Chemico Biological Interactions, 176 (2008) 212-219 [Publisher: Elsevier, IF: 3.10].
12.    V.V.S.Rajendra Prasad, Richard Honeywell, J.Venkat Rao, N.K.Sathish, S.M.Shanta Kumar,Y.C.Mayur , “Characteristic fragmentation behavior of some novel anti-calmodulin acridone derivatives studied by electrospray ionization tandem mass spectrometry” International Journal of Mass Spectrometry, 263 (2007) 148–151. [Publisher: Elsevier, IF: 2.5].
13.    Y.C.Mayur, Zaheeruddin, G.J.Peters, C.Lemos, I.Kethmann, V.V.S.Rajendra Prasad “Synthesis of 2-fluoro N10-substituted acridones and their cytotoxic studies in sensitive and resistant cancer cell lines and their DNA binding studies” Arch.Pharm.Chem.Life.Sci  (2009) 342, 640-650. [Publisher: Wiley Interscience, IF: 2.04].
14.    N. K. Sathish, V. V. S. Rajendra Prasad, N. M. Raghavendra, S. M. Shanta Kumar, Y. C. Mayur “Synthesis of Novel 1,3-Diacetoxy-Acridones as Cytotoxic Agents and their DNA-Binding Studies” Scientia Pharmaceutica (2009) 77, 19–32. [IFactor: 0.64].
15.    N. K. Sathish, P. GopKumar, V. V. S. Rajendra Prasad, S. M. Shanta Kumar, Y. C. Mayur “Synthesis, chemical characterization of novel 1,3-dimethyl acridones as cytotoxic agents, and their DNA-binding studies” Medicinal Chemistry Research (2009), 45, 456-462. [Publisher: Wiley Interscience IF: 0.73].
16.    Y.C. Mayur, V.V.S.Rajendra Prasad, N. Srinivasulu, S.M.Shanta Kumar. “Synthesis of 2-Methyl N10-Substituted Acridones as Selective Inhibitors of Multidrug Resistance (MDR) Associated Protein in Cancer Cells” Medicinal Chemistry, 4 (2008) 457-465. [Publisher: Bentham, IF: 2.60].
17.    Y.C. Mayur, M.Gouda, S.M. Shanta Kumar, V.V.S. Rajendra Prasad. “Synthesis and Chemical Characterization of N10-Substituted Acridones as Reversers of Multidrug Resistance in Cancer Cells" Letters In Drug Design & Discovery, 4 (2007) 327-335. [Publisher: Bentham, IF: 1.1].
18.    V.V.S.Rajendra Prasad, Y.Rajesh Babu, Y.C.Mayur, S.M. Shanta Kumar, “Synthesis of New Thiazolidin-4-one Substituted 1,2,4-Trizaloes As Antimicrobial Agents” Indian Journal Of Heterocyclic Chemistry, 16 (2006) 179-182. [IF: 0.25].
19.    N.K.Sathish, V.V.S.Rajendra Prasad, M.D.Karvekar, Y.C.Mayur. “Synthesis of New Fexofenadine Analogues  And Their Pharmacological Activity” Indian Journal Of Heterocyclic Chemistry, 16 (2006) 199-200. [IF: 0.25].
20.    Rajesh Kumar, V.V.S.Rajendra Prasad, Y.C.Mayur, S.M. Shanta Kumar, M.B.Raju. “Synthesis and Antimicrobial Activity of 2-[(5-substituted aryl-1’-N-Substituted aryl Aminomethyl) Pyrazol-3-yl] Benzofurans” Indian Journal of Heterocyclic Chemistry, 15 (2006) 245-248. [IF: 0.25].
21.    Soma Suresh, V.V.S. Rajendra Prasad, S.M. Shanta Kumar, Y.C.Mayur M.B.Raju. “Synthesis and Antimicrobial Activity of 1,2,4-Triazlyl Benzofurans” Indian Journal of Heterocyclic Chemistry, 15 (2006) 287-288. [IF: 0.25].

Achievements :

Grants Received:

Title: Development of Nitric oxide releasing Quinoline derivatives as inhibitors of doxorubicin resistance in cancer cells.
Funding Agency: VI–D&P/623/2018-19/TDT DPRP/DST.
Amount (INR): 1,41,00,000.
Duration: 3 Years.
PI/Co-PI: Dr.V.V.S.Rajendra Prasad & Dr.A.Ramesh.
Status: Sanctioned.

Title: Development and characterization of polymer based letrozole loaded na no particulate formulation to induce programmed cellular death in breast cancer,in vitro and invivo studies.
Funding Agency: ICMR, 3-2-217/2019
Amount (INR): 13,67,000.
Duration: 3 Years.
PI/Co-PI: Dr.V.V.S.Rajendra Prasad & Mrs M.Sandhya.
Status: Ongoing.

Title: Structural insights to inhibit Epidermal Growth Factor Receptor (EGFR) dimerization & activation: Panitumumab induced Conformational study.
Funding Agency: DBT, [6242-P55/RGCB/PBD/DBT,APDK/2015]
Amount (INR): 24,75,480.
Duration: 3 Years.
PI/Co-PI: Dr.V.V.S.Rajendra Prasad
Status: Completed.

Title: Travel Grant sanctioned to present research paper in the GTC conference “Protein Kinases and Drug Design” BOSTON, USA on 08-10th Nov, 2012.
Funding Agency: DST, [SR/ITS/3737/2012-13]
Amount (INR): 1,37,580.
Duration: 3 Years.
PI/Co-PI: Dr.V.V.S.Rajendra Prasad
Status: Completed.

Title: Mechanistic Studies: Acridones as reverters of multidrug resistance (MDR) in cancer
Funding Agency: AICTE, [1-51/RIFD/CA/11/2011-12]
Amount (INR): 9,00,000
Duration: 3 Years.
PI/Co-PI: Dr.V.V.S.Rajendra Prasad
Status: Completed.

Title: Design and Synthesis of nitric oxide donating phenoxazine derivatives as reverters of multidrug resistance (MDR) in cancer.
Funding Agency: SERB, [SR/FT/LS-75/2009]
Amount (INR): 18,02,000
Duration: 3 Years.
PI/Co-PI: Dr.V.V.S.Rajendra Prasad
Status: Completed.

Sucessfully completed 10 Coursera courses
 
Associate Professor - Dr.Ramanjaneyulu K.
Assistant Professor - Dr.B. Jahnavi
Associate Professor - Dr.V.Muralidharan
Assistant Professor - Dr.J. Hima bindhu
Assistant Professor - Mrs. S.Srujana
Assistant Professor - Mrs. Nameera Jabeen
Assistant Professor - Mr.Kirankumar
Assistant Professor - Mr.B.Kishore
Assistant Professor - Mr. Sai Kruparaj
Assistant Professor - G.Uday Bhaskar
Assistant Professor - Mrs. G.Flawrance
Assistant Professor - G. Shravani
Assistant Professor - H. Nikitha Sharma
Assistant Professor - M.Swathi
© 2022 VIPER | All Rights Reserved.